Study IDs potential treatment for deadly, HIV-related blood cancer

Researchers at the USC Norris Comprehensive Cancer Center have discovered a promising new way to treat a rare and aggressive blood cancer most commonly found in people infected with HIV.

The USC team shows that a class of drugs called BET bromodomain inhibitors effectively targets (PEL), a type of cancer for which those drugs were not expected to be effective.

"It's a reversal of the paradigm," said Preet Chaudhary, MD, PhD, chief of the Nohl Division of Hematology and at the Keck School of Medicine of USC and principal investigator of the study. "Our results suggest that this new class of drug may be an effective treatment for a wider range of cancers than previously thought."

PEL is caused by infection with Kaposi's sarcoma-associated herpes virus, the most common cause of cancer among patients with AIDS. The prognosis for PEL is poor, with a median survival of three to six months. Thus, there is a critical need for new therapies for the disease.

Chaudhary and his colleagues show that inhibitors targeting the BRD4 protein blocked growth of PEL cells in a test tube and in a . The results were surprising because BET inhibitors were thought to be only effective against cancers linked to an of the Myc gene.

"We actually found that cancers that overexpress Myc are not as responsive to BRD4 inhibitors. PEL is more responsive," Chaudhary said.

Cancers like and Burkitt's lymphoma overexpress the Myc gene and have been shown to respond to BRD4 inhibitors. In PEL, the Myc gene is moderately expressed and there is no chromosomal translocation as is seen in multiple myeloma or Burkitt's.

More research is needed to create compounds ready for testing in people. Once those drugs are ready for clinical trial, data from this study suggest that they may treat a wide range of cancers. Chaudhary anticipates testing them alone and in combination with other drugs.

The study, "Targeting Myc in KSHV-associated primary effusion lymphoma with BET bromodomain inhibitors," appears in Oncogene, a peer-reviewed scientific journal from the Nature Publishing Group.

More information: Tolani, B., Gopalakrishnan, R., Punj, V., Matta, H., & Chaudhary, P.M. (2013). Targeting Myc in KSHV-associated primary effusion lymphoma with BET bromodomain inhibitors. Oncogene. Published online June 24, 2013; doi:10.1038/onc.2013.242

Related Stories

Recommended for you

Scientists discover hidden subpopulation of melanoma cells

1 hour ago

UNC School of Medicine researchers have pinpointed a set of intriguing characteristics in a previously unknown subpopulation of melanoma cancer cells in blood vessels of tumors. These cells, which mimic non-cancerous ...

Blood biomarker may detect lung cancer

18 hours ago

A new study shows that patients with stage I to stage III non-small cell lung cancer have different metabolite profiles in their blood than those of patients who are at risk but do not have lung cancer. The study abstract ...

User comments